RE:RE:RE:RE:The CC, another possibility When we look in the May 10 message, we could perhaps have an answer to the conference call. The action plan for 2018 is the financial framework, the BLA's plasminogen action process and partnership initiatives. One or more milestones could be filled.
https://resources.prometic.com/press-releases-2018/prometic-reports-on-its-2018-annual-and-special-meeting-of-shareholders-highlights
Prometic's priority in 2018 is to bridge the gap between the fundamental value created in recent years and the current stock price that does not reflect all the institutional, clinical and operational milestones delivered. The roadmap to be accomplished is based on the following corporate action plan:
A financial framework that will make it possible to succeed by prioritizing projects, spending proportionately and controlling cash flow;
A strong action plan for the PLA plasminogen review process, in which an integrated multi-disciplinary team will review the entire new BLA submission with the assistance of an external group of specialized support services consultants regulatory affairs;
A human resource strategy that will focus on having the right people, with the right skills and the ability to deliver while focusing on managing growth;
A business development strategy focused on partnership initiatives focused on maximizing value by providing financial resources, participation in value creation, providing additional resources to reduce the risks of development programs while increasing International scope of Prometic;
and Continued advancement of three terminally active clinical assets with the ability for each to meet significant unmet medical needs.